From AI embryo selection to robotic ICSI, automation is reaching more parts of the IVF laboratory—but not at the same pace

Automation in IVF is no longer a futuristic concept.

AI can analyze and rank embryos.

Automated systems can assist vitrification.

Robotic and remotely operated systems have already been used for ICSI.

Researchers are even beginning to connect multiple laboratory procedures into integrated automated workflows.

That naturally raises a big question:

"How close are we to a fully automated IVF laboratory?"

A recent 2026 review examined the current evidence across four major technology domains:

AI-assisted embryo selection → Semi-automated vitrification → Robotic ICSI → End-to-end laboratory automation

The answer is more complicated than the technology headlines might suggest.

1. AI-assisted embryo selection: advanced technology, but an evolving clinical evidence base

AI-based embryo assessment is one of the most mature areas of IVF automation.

Retrospective studies have shown that AI systems can achieve performance comparable to, and in some settings greater than, conventional embryologist assessment. They can also help reduce assessment time and support more standardized embryo evaluation.

However, randomized trials have not yet demonstrated clear superiority in clinical outcomes.

This distinction matters.

The value of automation does not necessarily have to mean a higher pregnancy rate.

Improvements in workflow efficiency, reproducibility, and standardization may also represent meaningful clinical value.

2. Semi-automated vitrification: closer to routine clinical use

Among the four areas reviewed, semi-automated vitrification appears relatively advanced in terms of clinical evidence.

Multicenter randomized trials have reported clinical outcomes comparable to conventional manual vitrification.

That makes vitrification an interesting example of how automation may first enter the IVF laboratory:

not necessarily by outperforming experienced embryologists, but by delivering similar outcomes with a more standardized process.

3. Robotic ICSI: healthy births, but still early

ICSI is one of the most technically demanding procedures performed in the IVF laboratory.

Researchers have now developed automated and remotely operated systems capable of performing parts, or in some cases much of, the ICSI procedure, and healthy births have already been reported.

That sounds remarkably advanced. But the evidence remains limited.

Current studies are still largely proof-of-concept, and broader multicenter and randomized evidence will be required before robotic ICSI becomes comparable to established manual workflows.

The technology may be real, but its clinical maturity is still catching up.

4. End-to-end automation: connecting the entire workflow

Perhaps the most futuristic concept is not automating one laboratory task, but connecting several of them.

Researchers have begun developing systems that combine steps such as:

Sperm preparation → Oocyte handling → Sperm selection → ICSI

into increasingly integrated workflows.

Early clinical pilot studies suggest this is technically possible, but the evidence remains extremely limited.

The review highlights one end-to-end approach evaluated in only 11 patients, illustrating just how early this field still is.

So while a nearly autonomous IVF laboratory can now be demonstrated technologically, that is very different from saying it has been clinically validated.

What happens to the embryologist?

This may be the most interesting question raised by the review.

Much of the conversation around automation focuses on whether machines will eventually replace embryologists.

The more realistic scenario may be very different.

As automated systems take over more repetitive or standardized tasks, the embryologist’s role could increasingly shift toward:

Verifying automated results
Managing unusual or exceptional cases
Making higher-level clinical and laboratory judgments
Monitoring overall laboratory quality

In other words, automation may change what embryologists spend their time doing, rather than eliminate their role.

Are we automating the right things?

The review also points to an intriguing mismatch.

The IVF procedures receiving the most attention from automation developers are not necessarily the procedures where operator skill has the greatest influence on outcomes.

AI embryo selection, vitrification, and ICSI are attracting significant technological development.

Meanwhile, procedures such as PGT biopsy and tubing, where manual skill and operator variation can also matter, have received comparatively little attention from automation researchers.

This raises another useful question:

"Should we automate what is technologically easiest—or what would create the greatest clinical value?"

The automated IVF lab is coming, but not all at once

IVF laboratory automation is already happening.

But the evidence suggests that it will not arrive as a single moment when the entire laboratory suddenly becomes autonomous.

Some technologies are approaching routine clinical use.

Others have reached healthy births but remain experimental.

Others are still small pilot projects.

The future is therefore likely to develop task by task.

And as that happens, the important question may shift from:

“Can we automate this?”

to:

“Should we automate this, and how should people and technology divide the work?”

The next generation of IVF laboratories may ultimately be defined not by removing humans from the process, but by finding the right balance between automation, clinical evidence, and embryologist expertise.

How Automated Is the IVF Lab—Really?